サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1415416

真菌感染症診断市場：タイプ別、診断方法別、エンドユーザー別-2024-2030年の世界予測

Fungal Infections Diagnosis Market by Type, Diagnostic Method, End-User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
真菌感染症診断市場：タイプ別、診断方法別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

真菌感染症診断市場規模は2023年に20億9,000万米ドルと推計され、2024年には22億3,000万米ドルに達し、CAGR 6.96%で2030年には33億5,000万米ドルに達すると予測されます。

真菌感染症診断の世界市場

主な市場の統計
基準年[2023］ 20億9,000万米ドル
予測年[2024］ 22億3,000万米ドル
予測年 [2030] 33億5,000万米ドル
CAGR（%） 6.96%
真菌感染症診断 Market-IMG1

真菌感染症（真菌症）とは、真菌種（イースト菌またはカビ）によって引き起こされる感染症または疾患を指します。真菌感染症は皮膚や爪に最もよく見られますが、真菌は口、喉、肺、尿路にも感染症を引き起こすことがあります。真菌感染症には、白癬（はくせん）水虫、足爪真菌、イースト菌感染症、掌蹠膿疱症（しょうせきのうほうしょう）などがあります。真菌感染症の診断は、主に臨床検体の顕微鏡検査、病理組織検査、培養、X線検査、MRI検査、CT画像検査などの方法論に依存しています。世界中で真菌感染症が増加していることから、効果的な疾患検出技術に対する需要が急増しています。さらに、真菌感染症管理に対する認識を促進する政府の取り組みや、ヘルスケア施設へのアクセス拡大への取り組みが、真菌感染症診断の採用率上昇につながっています。しかし、分子的・遺伝子的真菌感染症診断の複雑さや、熟練した医療・臨床従事者の不足が、真菌感染症診断ソリューションの成長を阻害しています。さらに、不正確な診断結果や一貫性のない診断結果、製品承認に関する厳しい規制も、真菌感染症診断機器、ソリューション、サービスにとっての課題となっています。しかし、主要企業は診断技術の能力と精度を向上させるため、研究開発イニシアティブへの投資を急速に拡大しています。画像技術の進歩により、遠隔診断のためのデジタルソリューションが強化され、迅速診断技術に人工知能が導入されたことで、成長の機会がもたらされています。

地域別洞察

米国とカナダを中心とする南北アメリカは、真菌感染症に対する一般市民の意識の高まりにより、真菌感染症診断ツールの成熟地域となっています。南北アメリカは、強固な研究機関や医療インフラが存在することが特徴であり、様々な真菌感染症のタイムリーで正確な診断に貢献しています。PCRや次世代シーケンサーを含む診断技術の進歩は、診断プロセスを加速し、精度を向上させ、南北アメリカ地域における潜在的な致死リスクを低減しています。欧州では、真菌感染症の蔓延が顕著に増加しており、その主な原因は高齢者人口と免疫抑制状態にある人々です。真菌感染症に対する意識の高まりにより、効果的な診断ツールに対する需要が高まっています。欧州地域は旅行や移住が増加しており、様々な真菌病原体のイントロダクションや拡散に寄与しています。そのため医療従事者は、このようなリスクの高い環境における潜在的なアウトブレイクを効果的に管理するために、革新的な真菌感染症診断法を採用しています。研究開発への多額の投資と新興企業の増加がこの地域の特徴です。アジア太平洋（APAC）地域では、主に人口密度の上昇と真菌の増殖に有利な気候条件により、真菌感染症の発生が急増しています。中国、日本、インドを中心とするAPAC地域は、医療費の高騰と患者の意識の高まりにより、計り知れない可能性を秘めています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは真菌感染症診断市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、真菌感染症診断市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-真菌感染症診断市場の市場規模および予測は？

2-真菌感染症診断市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-真菌感染症診断市場における技術動向と規制の枠組みは？

4-真菌感染症診断市場における主要ベンダーの市場シェアは？

5-真菌感染症診断市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 真菌感染症の蔓延と効果的な診断方法の必要性
      • 真菌感染症管理の意識を高める政府の取り組み
      • 真菌感染症試験シリーズの良好な承認
    • 抑制要因
      • 分子的および遺伝的真菌感染症診断の複雑さ
    • 機会
      • 分子およびポイントオブケア診断技術の進歩
      • 真菌感染症の検出と診断における遠隔皮膚学の可能性
    • 課題
      • 診断方法の不正確さに伴う制限
  • 市場セグメンテーション分析
    • タイプ：患者の免疫力低下による日和見真菌感染症の発生率の増加
    • 診断方法：細胞生物学および分子生物学の進歩により、感染症検出に分子診断法が採用されるようになりました。
    • エンドユーザー：ヘルスケア費の拡大が真菌感染症診断のための病院の成長と重要性につながる
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 真菌感染症診断市場：タイプ別

  • 風土病の真菌感染症
  • 日和見真菌感染症
  • 皮下真菌感染症
  • 表在性真菌感染症
  • 全身性真菌感染症

第7章 真菌感染症診断市場診断方法別

  • 抗原検査
  • 皮膚科検査
  • 病理組織学
  • 微生物培養
  • 分子診断学
  • 血清学

第8章 真菌感染症診断市場：エンドユーザー別

  • 病院
  • ポイントオブケア設定
  • 調査機関
  • 専門クリニック

第9章 南北アメリカの真菌感染症診断市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の真菌感染症診断市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの真菌感染症診断市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析
    • 新製品発売と機能強化

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Alexion Pharmaceuticals, Inc.
    • Amgen Inc.
    • Associates of Cape COD, Inc. by Seikagaku Group company
    • Astellas Pharma Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • BioMerieux SA
    • Bruker Corporation
    • Danaher Corporation
    • Eli Lilly and Company
    • ELITech Group
    • Eurofins Viracor, LLC
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Immununexpress Inc.
    • IMMY
    • InBios International, Inc.
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Norgen Biotek Corp.
    • PerkinElmer, Inc.
    • Polysciences, Inc.
    • Qiagen N.V.
    • Siemens Healthineers
    • Takeda Pharmaceutical Company Limited
    • Thermo Fisher Scientific Inc.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. FUNGAL INFECTIONS DIAGNOSIS MARKET DYNAMICS
  • FIGURE 7. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2030 (%)
  • FIGURE 10. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SYSTEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 12. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOLOGICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 151. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. FUNGAL INFECTIONS DIAGNOSIS MARKET LICENSE & PRICING
目次
Product Code: MRR-346757DFA1EA

[194 Pages Report] The Fungal Infections Diagnosis Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.23 billion in 2024, at a CAGR 6.96% to reach USD 3.35 billion by 2030.

Global Fungal Infections Diagnosis Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.23 billion
Forecast Year [2030] USD 3.35 billion
CAGR (%) 6.96%
Fungal Infections Diagnosis Market - IMG1

Fungal infections, or mycosis, refer to infections or diseases caused by a fungus species (yeast or mold). Fungal infections are most commonly observed on the skin or nails, but fungi can also cause infections in the mouth, throat, lungs, and urinary tract. Fungal infections come in different forms, such as ringworm athlete's foot, toenail fungus, yeast infections, and jock itch. Diagnosis of fungal infection primarily relies on methodologies such as microscopic examination of clinical samples, histopathology, culture, X-rays, MRI, or CT imaging. The rising incidences of fungal infections across the world have led to a surge in demand for effective disease detection technologies. Furthermore, government initiatives promoting awareness of fungal infection management and efforts to expand access to healthcare facilities have led to rising adoption of fungal infection diagnosis. However, the complexity of molecular and genetic fungal infection diagnosis and the lack of skilled medical and clinical personnel impeded the growth of fungal infection diagnosis solutions. Additionally, inaccurate or inconsistent diagnosis results and stringent regulations pertaining to product approval also pose challenges for fungal infection diagnosis devices, solutions, and services. However, major players are rapidly expanding investments in R&D initiatives to improve the capabilities and accuracy of diagnosis technologies. Advances in imaging technologies enhanced digital solutions for remote diagnosis and the introduction of artificial intelligence in rapid diagnostic techniques present opportunities for growth.

Regional Insights

The Americas, specifically the US and Canada, present a mature region for fungal infections diagnostic tools, attributable to the increased public consciousness about fungal infections. Americas is characterized by the presence of robust research institutions and medical infrastructure, contributing to the timely and accurate diagnosis of various fungal infections. The technological advancements in diagnostic techniques, including PCR and next-generation sequencing, have accelerated the diagnosis process, improved accuracy, and reduced the potential risk of fatality in the Americas region. In Europe, the spread of fungal infections shows a significant increase, mostly attributed to the elderly population and those with immunosuppressive conditions. There is a rising demand for effective diagnostic tools driven by increased awareness about fungal infections. European region exhibits a rise in travel and migration, which contributes to the introduction and spread of various fungal pathogens. Medical practitioners, therefore, adopt innovative fungal infection diagnostics to manage the potential outbreaks in this high-risk environment effectively. Significant investments in R&D and a growing number of start-ups characterize this region. Asia-Pacific (APAC) region is witnessing an upsurge in the incidence of fungal infections, primarily due to escalating population density and climatic conditions that favor fungal growth. The APAC region, chiefly China, Japan, and India, shows immense potential due to escalating healthcare expenditure and a surge in patient awareness.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Fungal Infections Diagnosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Fungal Infections Diagnosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fungal Infections Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Endemic Fungal Infections
    • Opportunistic Fungal Infections
    • Subcutaneous Fungal Infections
    • Superficial Fungal Infections
    • Systemic Fungal Infections
  • Diagnostic Method
    • Antigen Testing
    • Dermatological Examination
    • Histopathology
    • Microbiological Culture
    • Molecular Diagnostics
    • Serology
  • End-User
    • Hospitals
    • Point-of-Care Settings
    • Research Institutions
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Fungal Infections Diagnosis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Fungal Infections Diagnosis Market?

3. What are the technology trends and regulatory frameworks in the Fungal Infections Diagnosis Market?

4. What is the market share of the leading vendors in the Fungal Infections Diagnosis Market?

5. Which modes and strategic moves are suitable for entering the Fungal Infections Diagnosis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Fungal Infections Diagnosis Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of fungal infections and need for effective diagnosis methods
      • 5.1.1.2. Government initiatives promoting awareness of fungal infection management
      • 5.1.1.3. Favorable approvals for fungal infection test series
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of molecular and genetic fungal infection diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in molecular and point-of-care diagnosis technologies
      • 5.1.3.2. Potential of teledermatology in fungal infection detection and diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with the inaccuracy of the diagnostic methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients
    • 5.2.2. Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
    • 5.2.3. End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Fungal Infections Diagnosis Market, by Type

  • 6.1. Introduction
  • 6.2. Endemic Fungal Infections
  • 6.3. Opportunistic Fungal Infections
  • 6.4. Subcutaneous Fungal Infections
  • 6.5. Superficial Fungal Infections
  • 6.6. Systemic Fungal Infections

7. Fungal Infections Diagnosis Market, by Diagnostic Method

  • 7.1. Introduction
  • 7.2. Antigen Testing
  • 7.3. Dermatological Examination
  • 7.4. Histopathology
  • 7.5. Microbiological Culture
  • 7.6. Molecular Diagnostics
  • 7.7. Serology

8. Fungal Infections Diagnosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Point-of-Care Settings
  • 8.4. Research Institutions
  • 8.5. Specialty Clinics

9. Americas Fungal Infections Diagnosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fungal Infections Diagnosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fungal Infections Diagnosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. New Product Launch & Enhancement
      • 12.3.1.1. University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis
      • 12.3.1.2. Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use
      • 12.3.1.3. University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. Alexion Pharmaceuticals, Inc.
    • 13.1.3. Amgen Inc.
    • 13.1.4. Associates of Cape COD, Inc. by Seikagaku Group company
    • 13.1.5. Astellas Pharma Inc.
    • 13.1.6. Becton, Dickinson and Company
    • 13.1.7. Bio-Rad Laboratories, Inc.
    • 13.1.8. BioMerieux SA
    • 13.1.9. Bruker Corporation
    • 13.1.10. Danaher Corporation
    • 13.1.11. Eli Lilly and Company
    • 13.1.12. ELITech Group
    • 13.1.13. Eurofins Viracor, LLC
    • 13.1.14. F. Hoffmann-La Roche AG
    • 13.1.15. Hologic, Inc.
    • 13.1.16. Immununexpress Inc.
    • 13.1.17. IMMY
    • 13.1.18. InBios International, Inc.
    • 13.1.19. Laboratory Corporation of America Holdings
    • 13.1.20. Merck KGaA
    • 13.1.21. Norgen Biotek Corp.
    • 13.1.22. PerkinElmer, Inc.
    • 13.1.23. Polysciences, Inc.
    • 13.1.24. Qiagen N.V.
    • 13.1.25. Siemens Healthineers
    • 13.1.26. Takeda Pharmaceutical Company Limited
    • 13.1.27. Thermo Fisher Scientific Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing